Log in

NASDAQ:ARIA - Ariad Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume15.70 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:ARIA
CUSIP04033A10
Phone+1-617-4940400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive ARIA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARIA and its competitors with MarketBeat's FREE daily newsletter.


Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions

What is Ariad Pharmaceuticals' stock symbol?

Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."

How were Ariad Pharmaceuticals' earnings last quarter?

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) issued its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to analyst estimates of $60.64 million. The company's revenue was up 133.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.

Has Ariad Pharmaceuticals been receiving favorable news coverage?

News coverage about ARIA stock has trended extremely negative on Saturday, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ariad Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave media headlines about the pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Ariad Pharmaceuticals.

Who are some of Ariad Pharmaceuticals' key competitors?

What other stocks do shareholders of Ariad Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Twitter (TWTR), Exelixis (EXEL), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals (ACHN), Array Biopharma (ARRY), Ford Motor (F), Netflix (NFLX) and Alphabet (GOOG).

What is Ariad Pharmaceuticals' official website?

The official website for Ariad Pharmaceuticals is http://www.ariad.com/.

How can I contact Ariad Pharmaceuticals?

Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.


MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  556 (Vote Outperform)
Underperform Votes:  443 (Vote Underperform)
Total Votes:  999
MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel